Korro Bio Inc. (KRRO), a biopharmaceutical company, has selected KRRO-111 as a development candidate for clinical advancement in the potential treatment of alpha-1 antitrypsin deficiency.
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that causes the depletion of protein in the lungs and liver, leading to pulmonary emphysema and/or hepatic cirrhosis. Affecting nearly 3.4 million people worldwide, the only current FDA-approved treatment for AATD is a once-weekly infusion of human plasma-derived AAT protein called augmentation therapy.
KRRO-111 is a proprietary, GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells.
In preclinical studies, the drug has demonstrated successful RNA-editing by more than 90% in cells, correcting AAT transcription in liver cells. In mice models, the production of circulating M-AAT protein indicates the potential to improve lung and liver manifestations of the disease.
The company plans to present data on the preclinical validation of KRRO-111 as a candidate in treating AATD.
KRRO is currently trading at $9.32, up 1.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.